{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:35:00Z","timestamp":1790804100042,"version":"4.1.0"},"reference-count":139,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.jpba.2023.115500","type":"journal-article","created":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T02:09:47Z","timestamp":1685498987000},"page":"115500","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Preclinical risk assessment strategy to mitigate the T-cell dependent immunogenicity of protein biotherapeutics: State of the art, challenges and future perspectives"],"prefix":"10.1016","volume":"234","author":[{"given":"Andrea","family":"Di Ianni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Barbero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Fraone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyra","family":"Cowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico Riccardi","family":"Sirtori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2023.115500_bib1","first-page":"658","article-title":"White paper assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides \u2014 harmonized terminology and tactical recommendations","volume":"16","author":"Shankar","year":"2014"},{"key":"10.1016\/j.jpba.2023.115500_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2015.01.003","article-title":"A fit-for-purpose strategy for the risk-based immunogenicity testing of biotherapeutics: a European industry perspective","volume":"417","author":"Kloks","year":"2015","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jpba.2023.115500_bib3","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.biologicals.2011.01.006","article-title":"Taking immunogenicity assessment of therapeutic proteins to the next level","volume":"39","author":"B\u00fcttel","year":"2011","journal-title":"Biologicals"},{"key":"10.1016\/j.jpba.2023.115500_bib4","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrd818","article-title":"Bioequivalence and the immunogenicity of biopharmaceuticals","volume":"1","author":"Schellekens","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jpba.2023.115500_bib5","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.autrev.2015.02.007","article-title":"Managing unwanted immunogenicity of biologicals","volume":"14","author":"Deehan","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jpba.2023.115500_bib6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrd2399","article-title":"Leader2008_proteint_therapeutics_review","volume":"7","author":"Leader","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jpba.2023.115500_bib7","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/nrrheum.2013.4","article-title":"Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis","volume":"9","author":"Van Schouwenburg","year":"2013","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.jpba.2023.115500_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2016.00021","article-title":"Immunogenicity to biotherapeutics - The role of anti-drug immune complexes","volume":"7","author":"Krishna","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jpba.2023.115500_bib9","article-title":"Evaluating and Reporting the Immunogenicity Impacts for Biological Products \u2014 a Clinical Pharmacology","volume":"18","author":"Wang","year":"2016","journal-title":"Perspective"},{"key":"10.1016\/j.jpba.2023.115500_bib10","first-page":"250","article-title":"Monoclonal antibodies, immunogenicity, and associated infusion","volume":"72","author":"Adam Cheifetz","year":"2005","journal-title":"Mt Sinai J. Med"},{"key":"10.1016\/j.jpba.2023.115500_bib11","first-page":"4","article-title":"Immunogenicity of recombinant human proteins: causes and consequences","volume":"Suppl. 251","author":"Schellekens","year":"2004","journal-title":"J. Neurol."},{"key":"10.1016\/j.jpba.2023.115500_bib12","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1128\/cdli.1.4.365-372.1994","article-title":"Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies?","volume":"1","author":"Kuus-Reichel","year":"1994","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"10.1016\/j.jpba.2023.115500_bib13","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/art.30209","article-title":"Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study","volume":"63","author":"Korswagen","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jpba.2023.115500_bib14","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/1529-0131(200107)44:7<1717::AID-ART299>3.0.CO;2-C","article-title":"Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab","volume":"44","author":"D\u2019Arcy","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jpba.2023.115500_bib15","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/j.intimp.2011.10.014","article-title":"Anti-erythropoietin and anti-thrombopoietin antibodies induced after administration of recombinant human erythropoietin","volume":"11","author":"Shin","year":"2011","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.jpba.2023.115500_bib16","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/ndt\/gfh1087","article-title":"Antibody-mediated pure red cell aplasia (PRCA): Epidemiology, immunogenicity and risks","volume":"20","author":"Macdougall","year":"2005","journal-title":"Nephrol. Dial. Transpl."},{"key":"10.1016\/j.jpba.2023.115500_bib17","first-page":"1","article-title":"Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use. Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use. Table of contents","volume":"44","author":"EMA","year":"2012","journal-title":"EMA Guide"},{"key":"10.1016\/j.jpba.2023.115500_bib19","article-title":"Products for Human Use(CHMP), Guideline on Immunogenicity assessment of therapeutic proteins","year":"2017","journal-title":"EMEA\/CHMP\/"},{"key":"10.1016\/j.jpba.2023.115500_bib20","unstructured":"U.S. Food and Drug Administration, ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin - Guidance for Industry, (2021) 1\u201312. \u3008http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/default.htm\u3009."},{"key":"10.1016\/j.jpba.2023.115500_bib21","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2174\/1389201023378175","article-title":"Immune responses to therapeutic proteins in humans - clinical significance, assessment and prediction","volume":"3","author":"Koren","year":"2002","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.jpba.2023.115500_bib22","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0167-5699(89)90081-9","article-title":"Immunogenecity signals 1,2,3. and 0","volume":"10","author":"Janeway","year":"1989","journal-title":"Immunol. Today"},{"key":"10.1016\/j.jpba.2023.115500_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2008.01.001","article-title":"Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products","volume":"333","author":"Koren","year":"2008","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jpba.2023.115500_bib24","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/nbt1303","article-title":"A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs","volume":"25","author":"Shankar","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jpba.2023.115500_bib25","doi-asserted-by":"crossref","first-page":"482","DOI":"10.2174\/138920108786786411","article-title":"Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins","volume":"9","author":"Beck","year":"2008","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.jpba.2023.115500_bib26","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S0264-410X(02)00703-X","article-title":"Priming characteristics of peptide mimotopes of carbohydrate antigens","volume":"21","author":"Monzavi-Karbassi","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.jpba.2023.115500_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0015252","article-title":"Trace levels of innate immune response modulating impurities (IIRMIs) synergize to break tolerance to therapeutic proteins","volume":"5","author":"Verthelyi","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.jpba.2023.115500_bib28","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1002\/jps.21672","article-title":"Evaluation of the Immuno-Stimulatory Potential of Stopper Extractables and Leachables by Using Dendritic Cells as Readout","volume":"98","author":"Mueller","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2023.115500_bib29","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.clim.2013.09.006","article-title":"T-cell dependent immunogenicity of protein therapeutics: preclinical assessment and mitigation","volume":"149","author":"Jawa","year":"2013","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jpba.2023.115500_bib30","doi-asserted-by":"crossref","first-page":"25118","DOI":"10.1074\/jbc.M110.160457","article-title":"Classification and characterization of therapeutic antibody aggregates","volume":"286","author":"Joubert","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jpba.2023.115500_bib31","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1208\/aapsj080359","article-title":"Effects of protein aggregates: an immunologic perspective","volume":"8","author":"Rosenberg","year":"2006","journal-title":"AAPS J."},{"key":"10.1016\/j.jpba.2023.115500_bib32","doi-asserted-by":"crossref","first-page":"25266","DOI":"10.1074\/jbc.M111.330902","article-title":"Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses","volume":"287","author":"Joubert","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jpba.2023.115500_bib33","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1586\/ecp.11.39","article-title":"Overcoming immunogenicity associated with the use of biopharmaceuticals","volume":"4","author":"Tovey","year":"2011","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.jpba.2023.115500_bib34","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/FTD.0000000000000404","article-title":"Ana; Rispens, Theo PhD, Immunogenicity of Therapeutic Antibodies: Monitoring Antidrug Antibodies in a Clinical Context","volume":"39","author":"Bloem","year":"2017","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jpba.2023.115500_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01301","article-title":"T-cell dependent immunogenicity of protein therapeutics pre-clinical assessment and mitigation\u2013updated consensus and review 2020","volume":"11","author":"Jawa","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jpba.2023.115500_bib36","doi-asserted-by":"crossref","unstructured":"M.D. Nicole Casadevall, M.D., Joelle Nataf, M.D., B\u00e9atrice Viron, M.D., Amir Kolta, P. Jean -Jacques Kiladjian, M.D., Philippe Martin-Dupont, M.D., Patrick Michaud, M.D., Thomas Papo, M.D., Val\u00e9rie Ugo, M.D., Ir\u00e8ne Teyssandier, B.S., Bruno Varet, M.D., and Patrick Mayeux, Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin, N. Engl. J. Med. 346 (2002) 469\u2013475.","DOI":"10.1056\/NEJMoa011931"},{"key":"10.1016\/j.jpba.2023.115500_bib37","first-page":"1403","author":"Nissenson","year":"2004","journal-title":"Pure Red. -Cell Apla Epoetin Ther."},{"key":"10.1016\/j.jpba.2023.115500_bib38","first-page":"367","volume":"1","author":"Rubic-schneider","year":"2017","journal-title":"T-Cell assays con fi rm immunogenicity Tungsten-Induc. Erythrop. Aggreg. Assoc. pure Red. Cell Apla"},{"key":"10.1016\/j.jpba.2023.115500_bib39","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1210\/jcem-51-4-691","article-title":"Role of aggregated human growth hormone (hGH) in development of antibodies to hGH","volume":"51","author":"Moore","year":"1980","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jpba.2023.115500_bib40","unstructured":"Lewis K. Inspiration biopharmaceuticals announces clinical hold of clinical trials evaluating IB1001 for the treatment and prevention of bleeding in hemophilia B. In: Inspiration Biopharmaceuticals (Chicago, IL: PRNewswire) (2012)., (n.d.)."},{"key":"10.1016\/j.jpba.2023.115500_bib41","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1111\/jth.13141","article-title":"Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity","volume":"13","author":"Mahlangu","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.jpba.2023.115500_bib42","first-page":"250","article-title":"Monoclonal antibodies, immunogenicity, and associated infusion reactions","volume":"72","author":"Adam Cheifet","year":"2005","journal-title":"Mt Sinai J. Med."},{"key":"10.1016\/j.jpba.2023.115500_bib43","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jim.2016.02.008","article-title":"Affinity capture elution bridging assay: a novel immunoassay format for detection of anti-therapeutic protein antibodies","volume":"431","author":"Chen","year":"2016","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jpba.2023.115500_bib44","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.yrtph.2007.07.005","article-title":"Detection of antibodies against therapeutic proteins in the presence of residual therapeutic protein using a solid-phase extraction with acid dissociation (SPEAD) sample treatment prior to ELISA","volume":"49","author":"Smith","year":"2007","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.jpba.2023.115500_bib45","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJMoa074943","article-title":"D. Ph, D. Ph, Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose- \u03b1-1,3-Galactose","volume":"358","author":"Hosen","year":"2008","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.jpba.2023.115500_bib46","doi-asserted-by":"crossref","unstructured":"M.B. Hock, K.E. Thudium, N.F. Schwabe, Meeting Report Immunogenicity of Antibody Drug Conjugates: Bioanalytical Methods and Monitoring Strategy for a Novel Therapeutic Modality, 17 (2015). https:\/\/doi.org\/10.1208\/s12248\u2013014-9684\u20136.","DOI":"10.1208\/s12248-014-9684-6"},{"key":"10.1016\/j.jpba.2023.115500_bib47","first-page":"55","author":"Hijazi","year":"2018","journal-title":"Pharmacokinet. Pharmacodyn. Relatsh. Blinatumomab Patients Non-Hodgkin Lymphoma"},{"key":"10.1016\/j.jpba.2023.115500_bib48","first-page":"195","author":"Pineda","year":"2016","journal-title":"Assess. Immunogenicity Biopharm."},{"key":"10.1016\/j.jpba.2023.115500_bib49","doi-asserted-by":"crossref","unstructured":"S.B. Cohen, A. Alonso-ruiz, P.A. Klimiuk, E.C. Lee, N. Peter, I. Sonderegger, D. Assudani, Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study, (2018) 914\u2013921. https:\/\/doi.org\/10.1136\/annrheumdis-2017\u2013212245.","DOI":"10.1136\/annrheumdis-2017-212245"},{"key":"10.1016\/j.jpba.2023.115500_bib50","unstructured":"F.E. Alvarez E., Steinman L., Neutralizing antibodies and antidrug antidodies in the ublituximab phase 3 ULTIMATE 1 and 2 studies in relapsing multiple sclerosis. Presented at ACTRIMS Forum 2022; February 24\u201326; West Palm Beach, FL. Abstract P103, (n.d.)."},{"key":"10.1016\/j.jpba.2023.115500_bib51","doi-asserted-by":"crossref","unstructured":"R.C. Murail, C. Goulvestre, S. Dumas, A. Molto, C. Miceli-richard, O. Conort, F. Batteux, Y. Allanore, Immunogenicity of Rituximab biosimilar GP2013 in chronic in fl ammatory rheumatic disorders in daily clinical practice r o, 52 (2022). https:\/\/doi.org\/10.1016\/j.semarthrit.2022.151951.","DOI":"10.1016\/j.semarthrit.2022.151951"},{"key":"10.1016\/j.jpba.2023.115500_bib52","doi-asserted-by":"crossref","unstructured":"J.S. Smolen, S.B. Cohen, H. Tony, M. Scheinberg, A. Kivitz, A. Balanescu, J. Gomez-reino, L. Cen, J. Poetzl, T. Shisha, D. Kollins, Concise report Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial, (2021) 256\u2013262. https:\/\/doi.org\/10.1093\/rheumatology\/keaa234.","DOI":"10.1093\/rheumatology\/keaa234"},{"key":"10.1016\/j.jpba.2023.115500_bib53","first-page":"16","author":"Neurologic","year":"2017","journal-title":"C. Or. R. e Sp. ondence Antidrug Antibodies Patients Treat. Alirocumab"},{"key":"10.1016\/j.jpba.2023.115500_bib54","volume":"41","author":"Wegener","year":"1999","journal-title":"Saf. Effic. ofArcitumomab Imaging Colorectal Cancer Repeated Adm."},{"key":"10.1016\/j.jpba.2023.115500_bib55","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/j.jid.2018.04.019","article-title":"Ixekizumab pharmacokinetics, anti-drug antibodies, and efficacy through 60 weeks of treatment of moderate to severe plaque psoriasis","volume":"138","author":"Reich","year":"2018","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jpba.2023.115500_bib56","first-page":"539","author":"Deodhar","year":"2020","journal-title":"Secukinumab Immunogenicity 52 Weeks Patients Psoriatic Arthritis Ankyl. Spondylitis"},{"key":"10.1016\/j.jpba.2023.115500_bib57","doi-asserted-by":"crossref","unstructured":"K. Bendtzen, P. Geborek, M. Svenson, L. Larsson, M.C. Kapetanovic, T. Saxne, Individualized Monitoring of Drug Bioavailability and Immunogenicity in Rheumatoid Arthritis Patients Treated With the Tumor Necrosis Factor \u2423 Inhibitor Infliximab, 54 (2006) 3782\u20133789. https:\/\/doi.org\/10.1002\/art.22214.","DOI":"10.1002\/art.22214"},{"key":"10.1016\/j.jpba.2023.115500_bib58","doi-asserted-by":"crossref","unstructured":"R.N. Maini, F.C. Breedveld, J.R. Kalden, J.S. Smolen, D. Davis, J.D. Macfarlane, C. Antoni, B. Leeb, M.J. Elliott, J.N. Woody, T.F. Schaible, M. Feldma, Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor \u03b1 monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis, (1998) 1552\u20131563.","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W"},{"key":"10.1016\/j.jpba.2023.115500_bib59","author":"Ruf","year":"2010","journal-title":"immunogenicity bioactivity Ther. Antib. catumaxomab intraperitoneally Adm. Cancer Patients"},{"key":"10.1016\/j.jpba.2023.115500_bib60","doi-asserted-by":"crossref","unstructured":"A. Burges, C. Ku, V. Gorbounova, H. Sommer, B. Schmalfeldt, J. Pfisterer, M. Lichinitser, A. Makhson, V. Moiseyenko, A. Lahr, E. Schulze, M.A. Stro, M.M. Heiss, T. Gottwald, H. Lindhofer, R. Kimmig, Cancer Therapy: Clinical Effective Relief of Malignant Ascites in Patients with Advanced Ovarian Cancer by a Trifunctional Anti-EpCAM x Anti-CD3 Antibody: A Phase I \/ II Study, 13 (2007) 3899\u20133905. https:\/\/doi.org\/10.1158\/1078\u20130432.CCR-06\u20132769.","DOI":"10.1158\/1078-0432.CCR-06-2769"},{"key":"10.1016\/j.jpba.2023.115500_bib61","unstructured":"A.C. Per Soelberg-Sorensen, Douglas Arnold, Jeffrey Cohen, Alasdair Coles, Christian Confavreux, Edward Fox, Hans Hartung, Eva Havrdova, Krzysztof Selmaj, Howard Weiner, Tamara Miller, Cary Twyman, Stephen Lake, David Margolin, Susan Richards, Crystal Sung, Mi, Immunogenicity of Alemtuzumab Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients in the CARE-MS II Study (P07.101), (n.d.)."},{"key":"10.1016\/j.jpba.2023.115500_bib62","unstructured":"AVASTIN (bevacizumab) Prescribing Information, (2022)."},{"key":"10.1016\/j.jpba.2023.115500_bib63","doi-asserted-by":"crossref","unstructured":"M. Outcomes, T. Registration, Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration A Randomized Clinical Trial, 21287 (2021) 68\u201376. https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.5053.","DOI":"10.1001\/jamaophthalmol.2020.5053"},{"key":"10.1016\/j.jpba.2023.115500_bib64","first-page":"169","volume":"2","author":"Ferrero","year":"2016","journal-title":"Study aducanumab ( BIIB037) mild-to-Moderat. Alzheimer \u2019 S. Dis."},{"key":"10.1016\/j.jpba.2023.115500_bib65","first-page":"1047","volume":"23","author":"Sandborn","year":"2017"},{"key":"10.1016\/j.jpba.2023.115500_bib67","first-page":"1142","author":"Ma","year":"2009","journal-title":"Popul. Pharmacokinet. Anal. Panitumumab Patients Adv. Solid Tumors"},{"key":"10.1016\/j.jpba.2023.115500_bib68","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1016\/j.cgh.2019.11.059","article-title":"Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis","volume":"18","author":"Adedokun","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jpba.2023.115500_bib69","first-page":"1715","author":"Iguchi","year":"2019","journal-title":"Tolerability Effic. durvalumab Jpn. Patients Adv. Solid Tumors"},{"key":"10.1016\/j.jpba.2023.115500_bib70","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S1470-2045(15)00544-6","article-title":"Safety and antitumour activity of durvalumab plus tremelimumab in non-small-cell lung cancer: a multicentre, phase 1b study","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jpba.2023.115500_bib71","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1200\/JCO.2007.11.7812","article-title":"High incidence of cetuximab-related infusion reactions in tennessee and north carolina and the association with atopic history","volume":"25","author":"Neil","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jpba.2023.115500_bib72","unstructured":"Bavencio (avelumab) Prescribing Information; 2017. https:\/\/www.accessdata. fda.gov\/drugsatfda_docs\/label\/2017\/761078s000lbl.pdf. Accessed 16 Oct 2018. 45. Health Canada Prescribing Information Bavencio, avelumab for injection., (n.d.)."},{"key":"10.1016\/j.jpba.2023.115500_bib74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/2162402X.2018.1424674","article-title":"Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab","volume":"7","author":"Kverneland","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jpba.2023.115500_bib75","unstructured":"Tecentriq (atezolizumab) Prescribing Information; 2018. https:\/\/www.gene. com\/download\/pdf\/tecentriq_prescribing.pdf. Accessed 16 Oct 2018., (n.d.)."},{"key":"10.1016\/j.jpba.2023.115500_bib76","unstructured":"Darzalex (daratumumab) Prescribing Information. 2018. http:\/\/www. janssenlabels.com\/package-insert\/product-monograph\/prescribing_information\/DARZALEX-pi.pdf. Accessed 11 Feb 2019., (n.d.)."},{"key":"10.1016\/j.jpba.2023.115500_bib77","unstructured":"ADCETRIS\u00ae (brentuximab vedotin) prescribing information https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/125388s097lbl.pdf., (2011) 1\u201335."},{"key":"10.1016\/j.jpba.2023.115500_bib78","unstructured":"KADCYLA\u00ae (ado-trastuzumab emtansine) prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125427s105lbl.pdf, (2019)."},{"key":"10.1016\/j.jpba.2023.115500_bib80","doi-asserted-by":"crossref","unstructured":"A. Sauter, C. Kloft, S. Gronau, F. Bogeschdorfer, T. Erhardt, W. Golze, C. Schroen, A. Staab, H. Riechelmann, K. Hoermann, Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck, (2007) 927\u2013935.","DOI":"10.3892\/ijo.30.4.927"},{"key":"10.1016\/j.jpba.2023.115500_bib81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/1298473","article-title":"Immunogenicity of biotherapeutics: causes and association with posttranslational modifications","author":"Kuriakose","year":"2016","journal-title":"J. Immunol. Res"},{"key":"10.1016\/j.jpba.2023.115500_bib82","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00292","article-title":"Major histocompatibility complex (MHC) class I and MHC class II proteins: Conformational plasticity in antigen presentation","volume":"8","author":"Wieczorek","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jpba.2023.115500_bib83","first-page":"415","article-title":"Revisiting nonclassical","volume":"96","author":"\u00c1lvaro-Benito","year":"2020","journal-title":"HLA II Funct. Antigen. Present.: Pept. Ed. its Modul., HLA"},{"key":"10.1016\/j.jpba.2023.115500_bib84","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1034\/j.1600-065X.2000.00607.x","article-title":"B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms","volume":"176","author":"Wu","year":"2000","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.jpba.2023.115500_bib85","first-page":"1192","article-title":"Autoantibodies to variable heavy ( V H) chain Ig sequences in humans impact the safety and clinical pharmacology of a V H domain antibody antagonist of TNF- \u03b1","volume":"1","author":"Holland","year":"2013","journal-title":"Receptor"},{"key":"10.1016\/j.jpba.2023.115500_bib86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2021.782788","article-title":"Immune Complex Formation Is Associated With Loss of Tolerance and an Antibody Response to Both Drug and Target","volume":"12","author":"Kroenke","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jpba.2023.115500_bib87","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1136\/annrheumdis-2016-210459","article-title":"Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study","volume":"76","author":"Cohen","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jpba.2023.115500_bib88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-018-1646-4","article-title":"A randomized controlled trial comparing PF-06438179\/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy","volume":"20","author":"Cohen","year":"2018","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jpba.2023.115500_bib89","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1124\/jpet.301.2.418","article-title":"Binding and functional comparisons of two types of tumor necrosis factor antagonists","volume":"301","author":"Scallon","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jpba.2023.115500_bib91","first-page":"9231","volume":"98","author":"Mcfarland","year":"2001","journal-title":"Energ. asymmetry Hydrog. Bonds MHC Cl. II Pept. Complex."},{"key":"10.1016\/j.jpba.2023.115500_bib92","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.4049\/jimmunol.162.6.3463","article-title":"Sodium Dodecyl Sulfate Stability of HLA-DR1 Complexes Correlates with Burial of Hydrophobic Residues in Pocket 1","volume":"162","author":"Natarajan","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.jpba.2023.115500_bib93","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.coi.2014.12.005","article-title":"ScienceDirect Determinants of immunodominance for CD4 T cells","volume":"34","author":"Kim","year":"2015","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.jpba.2023.115500_bib94","doi-asserted-by":"crossref","first-page":"25907","DOI":"10.1074\/jbc.M003459200","article-title":"Gamma-interferon-inducible lysosomal thiol reductase (GILT): Maturation, activity, and mechanism of action","volume":"275","author":"Phan","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jpba.2023.115500_bib95","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1146\/annurev-immunol-082119-124838","article-title":"T Cell Epitope Predictions","volume":"38","author":"Peters","year":"2020","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jpba.2023.115500_bib96","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jim.2010.10.010","article-title":"Applications for T-cell epitope queries and tools in the Immune Epitope Database and Analysis Resource","volume":"374","author":"Kim","year":"2011","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jpba.2023.115500_bib97","doi-asserted-by":"crossref","first-page":"W502","DOI":"10.1093\/nar\/gkz452","article-title":"IEDB-AR: immune epitope database - analysis resource in 2019","volume":"47","author":"Dhanda","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jpba.2023.115500_bib98","doi-asserted-by":"crossref","first-page":"6720","DOI":"10.4049\/jimmunol.166.11.6720","article-title":"Naturally Processed HLA Class II Peptides Reveal Highly Conserved Immunogenic Flanking Region Sequence Preferences That Reflect Antigen Processing Rather Than Peptide-MHC Interactions","volume":"166","author":"Godkin","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.jpba.2023.115500_bib99","first-page":"163","author":"Valmori","year":"2007","journal-title":"Epitope Clust. Reg. Under Effic. Protea Process. Defin. immunodominant CTL Reg. a Tumor Antigen."},{"key":"10.1016\/j.jpba.2023.115500_bib100","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4049\/jimmunol.152.1.163","article-title":"Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains","volume":"152","author":"Alerts","year":"1994","journal-title":"J. Immunol."},{"issue":"11","key":"10.1016\/j.jpba.2023.115500_bib101","first-page":"683","volume":"0201","author":"Liebert","year":"2004","journal-title":"Epitopes: QSAR Stud. Pept. Having Affin. Cl. I MHC Mol. HLA-A *"},{"key":"10.1016\/j.jpba.2023.115500_bib102","first-page":"121","volume":"14","author":"Brusic","year":"1998","journal-title":"Predict. MHC Cl. II-Bind. Pept. Using Evolut. Algorithm Artif. Neural Netw."},{"key":"10.1016\/j.jpba.2023.115500_bib103","first-page":"753","volume":"5","author":"Milik","year":"1998","journal-title":"Appl. Artif. Neural Netw. Predict Specif. Cl. I MH C. Bind. Pept. Seq."},{"key":"10.1016\/j.jpba.2023.115500_bib104","first-page":"423","volume":"43","author":"Robinson","year":"2015","journal-title":"IPD IMGT \/ HLA Database.: allele Var. Database."},{"key":"10.1016\/j.jpba.2023.115500_bib105","first-page":"449","article-title":"NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand","volume":"48","author":"Reynisson","year":"2020","journal-title":"data"},{"key":"10.1016\/j.jpba.2023.115500_bib106","first-page":"344","volume":"45","author":"Nielsen","year":"2017","journal-title":"NNAlign: a Platf. Constr. Eval. Artif. Neural Netw. Models Recept. \u2013 Ligand Interact."},{"key":"10.1016\/j.jpba.2023.115500_bib107","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/imm.13274","article-title":"Improved prediction of HLA antigen presentation hotspots: Applications for immunogenicity risk assessment of therapeutic proteins","volume":"162","author":"Attermann","year":"2021","journal-title":"Immunology"},{"key":"10.1016\/j.jpba.2023.115500_bib108","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01304","article-title":"Immunopeptidomic Data Integration to Artificial Neural Networks Enhances Protein-Drug Immunogenicity Prediction","volume":"11","author":"Barra","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jpba.2023.115500_bib109","doi-asserted-by":"crossref","unstructured":"V. Jurtz, S. Paul, M. Andreatta, NetMHCpan-4.0: Improved Peptide \u2212 MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data, 199 (2017) 3360\u20133368. https:\/\/doi.org\/10.4049\/jimmunol.1700893.","DOI":"10.4049\/jimmunol.1700893"},{"key":"10.1016\/j.jpba.2023.115500_bib110","unstructured":"S. Kumar, R.H. Robins, P.M. Buck, T.P. Hickling, A.M. Thangakani, L. Li, S.K. Singh, M.M. Gromiha, S.B. Dixit, N.J. Agrawal, N. Chennamsetty, T.D. Jones, A.C. Karle, M.P. Baker, P. Singh, A. Tiwari, A.K. Abraham, A. Zutshi, Developability of Biotherapeutics Computational Approaches, 2015."},{"key":"10.1016\/j.jpba.2023.115500_bib111","first-page":"961","volume":"203","author":"Steere","year":"2006","journal-title":"Antibiot. -Refract. Lyme Arthritis Is. Assoc. HLA-DR Mol. that Bind a Borrelia Burgd. Pept."},{"key":"10.1016\/j.jpba.2023.115500_bib112","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.4049\/jimmunol.174.6.3187","article-title":"Rationally Engineered Therapeutic Proteins with Reduced Immunogenicity","volume":"174","author":"Tangri","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.jpba.2023.115500_bib113","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1038\/s41596-019-0133-y","article-title":"Mass spectrometry\u2013based identification of MHC-bound peptides for immunopeptidomics","volume":"14","author":"Purcell","year":"2019","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.jpba.2023.115500_bib114","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1080\/19420862.2015.1136761","article-title":"Secukinumab, a novel anti\u2013IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity","volume":"8","author":"Karle","year":"2016","journal-title":"MAbs"},{"key":"10.1016\/j.jpba.2023.115500_bib115","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00500","article-title":"Characterization of CD4 T cell epitopes of infliximab and rituximab identified from healthy donors","volume":"8","author":"Hamze","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jpba.2023.115500_bib116","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1080\/19420862.2018.1518888","article-title":"MHC-associated peptide proteomics enabling highly sensitive detection of immunogenic sequences for the development of therapeutic antibodies with low immunogenicity","volume":"10","author":"Sekiguchi","year":"2018","journal-title":"MAbs"},{"key":"10.1016\/j.jpba.2023.115500_bib117","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1021\/acs.jproteome.0c00309","article-title":"Enabling Routine MHC-II-Associated Peptide Proteomics for Risk Assessment of Drug-Induced Immunogenicity","volume":"19","author":"Steiner","year":"2020","journal-title":"J. Proteome Res"},{"key":"10.1016\/j.jpba.2023.115500_bib118","doi-asserted-by":"crossref","unstructured":"A. Di Ianni, T. Fraone, P. Balestra, K.J. Cowan, F. Riccardi, Assessing Major Histocompatibility Complex-Associated Peptide Proteomics assay as a tool to predict immunogenicity potential of protein therapeutics and antigens, Submiss. (2023).","DOI":"10.26508\/lsa.202302095"},{"key":"10.1016\/j.jpba.2023.115500_bib119","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jaci.2005.04.019","article-title":"Bet v 1142-156 is the dominant T-cell epitope of the major birch pollen allergen and important for cross-reactivity with Bet v 1-related food allergens","volume":"116","author":"Jahn-Schmid","year":"2005","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jpba.2023.115500_bib120","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/s41591-019-0568-2","article-title":"A single T cell epitope drives the neutralizing anti-drug antibody response to natalizumab in multiple sclerosis patients","volume":"25","author":"Cassotta","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.jpba.2023.115500_bib121","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/19420862.2019.1707418","article-title":"T cell epitope mapping of secukinumab and ixekizumab in healthy donors","volume":"12","author":"Spindeldreher","year":"2020","journal-title":"MAbs"},{"key":"10.1016\/j.jpba.2023.115500_bib122","first-page":"1","volume":"7","author":"Karle","year":"2012","journal-title":"Nitration Pollen Allerg. Bet. V. 1. 0101 Enhanc. Present. Bet. V. 1-Deriv. Pept. HLA-DR Hum. Dendritic Cells"},{"key":"10.1016\/j.jpba.2023.115500_bib123","first-page":"1","volume":"10","author":"Grifoni","year":"2019","journal-title":"Charact. Magnit. Antigen. Specif. HLA-DP, DQ, DRB3\/4\/5 Restricted DENV-Specif. CD4+ T Cell Responses"},{"key":"10.1016\/j.jpba.2023.115500_bib124","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1182\/bloodadvances.2018030452","article-title":"Peptides identified on monocyte-derived dendritic cells: A marker for clinical immunogenicity to FVIII products","volume":"3","author":"Jankowski","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.jpba.2023.115500_bib125","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2020.1764829","article-title":"Post-hoc assessment of the immunogenicity of three antibodies reveals distinct immune stimulatory mechanisms","volume":"12","author":"Walsh","year":"2020","journal-title":"MAbs"},{"key":"10.1016\/j.jpba.2023.115500_bib126","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jim.2009.11.006","article-title":"Optimization of a dendritic cell-based assay for the in vitro priming of na\u00efve human CD4+ T cells","volume":"353","author":"Moser","year":"2010","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jpba.2023.115500_bib127","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1002\/eji.200636783","article-title":"Differential capacity of T cell priming in naive donors of promiscuous CD4+ T cell epitopes of HCV NS3 and core proteins","volume":"37","author":"Castelli","year":"2007","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jpba.2023.115500_bib128","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jim.2013.03.004","article-title":"Usage of standardized antigen-presenting cells improves ELISpot performance for complex protein antigens","volume":"391","author":"Navarrete","year":"2013","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jpba.2023.115500_bib129","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2893.2010.01430.x","article-title":"CD154, a marker of antigen-specific stimulation of CD4 T cells, is associated with response to treatment in patients with chronic HCV infection","volume":"18","author":"M\u00f6ller","year":"2011","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.jpba.2023.115500_bib130","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.clim.2010.06.018","article-title":"Considerations for optimization and validation of an in vitro PBMC derived T cell assay for immunogenicity prediction of biotherapeutics","volume":"137","author":"Wullner","year":"2010","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jpba.2023.115500_bib131","first-page":"1","article-title":"Quantitative analysis of the CD4","author":"Schultz","year":"2017","journal-title":"T Cell. Response Ther. antibodies Healthy donors Using a Nov. T Cell.: PBMC Assay."},{"key":"10.1016\/j.jpba.2023.115500_bib132","volume":"6901","author":"Ito","year":"2019","journal-title":"Vitr. Hum. Help. T-Cell Assay. Screen Antib. Drug Candidates immunogenicity"},{"key":"10.1016\/j.jpba.2023.115500_bib133","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1538-7836.2007.02336.x","article-title":"Depletion of CD4+\/CD25high regulatory T cells may enhance or uncover factor VIII-specific T-cell responses in healthy individuals","volume":"5","author":"Kamat\u00e9","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.jpba.2023.115500_bib134","doi-asserted-by":"crossref","unstructured":"L. Xue, T. Hickling, R. Song, J. Nowak, B. Rup, Contribution of enhanced engagement of antigen presentation machinery to the clinical immunogenicity of a human interleukin ( IL) -21 receptor-blocking therapeutic antibody, (2015) 102\u2013113. https:\/\/doi.org\/10.1111\/cei.12711.","DOI":"10.1111\/cei.12711"},{"key":"10.1016\/j.jpba.2023.115500_bib135","first-page":"584","volume":"70","author":"Rosenberg","year":"2018","journal-title":"Immunogenicity Assess. Dev. Protein Ther."},{"key":"10.1016\/j.jpba.2023.115500_bib136","first-page":"1","author":"Wen","year":"2020","journal-title":"Dev. a FRET-Based Assay. Anal. mAbs Intern. Process. Dendritic Cells Preclin. Immunogenicity Risk Assess."},{"key":"10.1016\/j.jpba.2023.115500_bib137","first-page":"703","volume":"14","author":"Melendez","year":"2022","journal-title":"Introd. dendritic Cell Antib. Intern. immunogenicity risk Assess. Tool."},{"key":"10.1016\/j.jpba.2023.115500_bib138","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.intimp.2014.08.002","article-title":"THP-1 cell line: An in vitro cell model for immune modulation approach","volume":"23","author":"Chanput","year":"2014","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.jpba.2023.115500_bib139","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2021.113147","article-title":"Comparability study of monocyte derived dendritic cells, primary monocytes, and THP1 cells for innate immune responses","volume":"498","author":"Wen","year":"2021","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jpba.2023.115500_bib140","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1898831","article-title":"Immunogenicity risk assessment for biotherapeutics through in vitro detection of CD134 and CD137 on T helper cells","volume":"13","author":"Cohen","year":"2021","journal-title":"MAbs"},{"key":"10.1016\/j.jpba.2023.115500_bib141","first-page":"137","author":"Immunology","year":"2012","journal-title":"Alter. Immunoregul. Profile anti-Tumour necrosis Factor Treat. Patients Inflamm. bowel Dis."},{"key":"10.1016\/j.jpba.2023.115500_bib142","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/19420862.2021.1993522","article-title":"Assay format diversity in pre-clinical immunogenicity risk assessment: toward a possible harmonization of antigenicity assays","volume":"14","author":"Ducret","year":"2022","journal-title":"MAbs"},{"key":"10.1016\/j.jpba.2023.115500_bib143","doi-asserted-by":"crossref","unstructured":"B. Rup, M. Pallardy, D. Sikkema, C. Carini, P. Creeke, D. Finco, C. Mauri, V. Mikol, Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium, (2015) 385\u2013400. https:\/\/doi.org\/10.1111\/cei.12652.","DOI":"10.1111\/cei.12652"},{"issue":"2017 (","key":"10.1016\/j.jpba.2023.115500_bib144","article-title":"Fundamentals and methods for T- and B-cell epitope prediction","author":"Sanchez-Trincado","year":"2017","journal-title":"J. Immunol. Res"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708523002698?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708523002698?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:28:24Z","timestamp":1760002104000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708523002698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":139,"alternative-id":["S0731708523002698"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2023.115500","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical risk assessment strategy to mitigate the T-cell dependent immunogenicity of protein biotherapeutics: State of the art, challenges and future perspectives","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2023.115500","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115500"}}